Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3001 AL 3015

Mechanisms of NLRP3 Inflammasome Activation: Its Role in the Treatment of Alzheimer's Disease

Zhang Y, Zhao Y, Zhang J, Yang G.

Neurochem Res. 2020 Nov;45(11):2560-2572. doi: 10.1007/s11064-020-03121-z. Epub 2020 Sep 14.

Alzheimer's disease: natural products as inhibitors of neuroinflammation

Olajide OA, Sarker SD.

Inflammopharmacology. 2020 Dec;28(6):1439-1455. doi: 10.1007/s10787-020-00751-1. Epub 2020 Sep 15.

Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets

Uddin MS, Al Mamun A, Kabir MT, Ashraf GM, Bin-Jumah MN, Abdel-Daim MM.

Mol Neurobiol. 2021 Jan;58(1):281-303. doi: 10.1007/s12035-020-02116-9. Epub 2020 Sep 15.

Alzheimer's disease: Recent treatment strategies

Vaz M, Silvestre S.

Eur J Pharmacol. 2020 Nov 15;887:173554. doi: 10.1016/j.ejphar.2020.173554. Epub 2020 Sep 15.

The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer's disease animal model: A systematic review

Zhang S, Zhu Q, Chen JY, OuYang D, Lu JH.

Phytomedicine. 2020 Dec;79:153316. doi: 10.1016/j.phymed.2020.153316. Epub 2020 Aug 31.

Multifunctional nano-enabled delivery systems in Alzheimer's disease management

Qian C , Yuan C , Li C , Liu H , Wang X .

Biomater Sci. 2020 Oct 21;8(20):5538-5554. doi: 10.1039/d0bm00756k. Epub 2020 Sep 21.

Integrated meta-analysis, network pharmacology, and molecular docking to investigate the efficacy and potential pharmacological mechanism of Kai-Xin-San on Alzheimer's disease

Yi P, Zhang Z, Huang S, Huang J, Peng W, Yang J.

Pharm Biol. 2020 Dec;58(1):932-943. doi: 10.1080/13880209.2020.1817103.

The efficacy and safety of hachimijiogan for mild Alzheimer disease in an exploratory, open standard treatment controlled, randomized allocation, multicenter trial: A study protocol

Kainuma M, Funakoshi K, Ouma S, Yamashita KI, Ohara T, Yoshiiwa A, Murata M, Tsuboi Y.

Medicine (Baltimore). 2020 Sep 18;99(38):e22370. doi: 10.1097/MD.0000000000022370.

The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease

Maskery M, Goulding EM, Gengler S, Melchiorsen JU, Rosenkilde MM, Hölscher C.

Am J Alzheimers Dis Other Demen. 2020 Jan-Dec;35:1533317520953041. doi: 10.1177/1533317520953041.

Tubulin modifying enzymes as target for the treatment of tau-related diseases

Rogowski K, Hached K, Crozet C, van der Laan S.

Pharmacol Ther. 2021 Feb;218:107681. doi: 10.1016/j.pharmthera.2020.107681. Epub 2020 Sep 19.

Human Pluripotent Stem Cell-Derived Neural Cells as a Relevant Platform for Drug Screening in Alzheimer's Disease

Garcia-Leon JA, Caceres-Palomo L, Sanchez-Mejias E, Mejias-Ortega M, Nuñez-Diaz C, Fernandez-Valenzuela JJ, Sanchez-Varo R, Davila JC, Vitorica J, Gutierrez A.

Int J Mol Sci. 2020 Sep 18;21(18):6867. doi: 10.3390/ijms21186867.

Mitochondrial Calcium Deregulation in the Mechanism of Beta-Amyloid and Tau Pathology

Esteras N, Abramov AY.

Cells. 2020 Sep 21;9(9):2135. doi: 10.3390/cells9092135.

Microbiota modulation as preventative and therapeutic approach in Alzheimer's disease

Bonfili L, Cecarini V, Gogoi O, Gong C, Cuccioloni M, Angeletti M, Rossi G, Eleuteri AM.

FEBS J. 2021 May;288(9):2836-2855. doi: 10.1111/febs.15571. Epub 2020 Oct 8.

Human-induced pluripotent stem cells as a model for studying sporadic Alzheimer's disease

Riemens RJM, Kenis G, van den Beucken T.

Neurobiol Learn Mem. 2020 Nov;175:107318. doi: 10.1016/j.nlm.2020.107318. Epub 2020 Sep 22.

Translating genetic risk of Alzheimer's disease into mechanistic insight and drug targets

Sierksma A, Escott-Price V, De Strooper B.

Science. 2020 Oct 2;370(6512):61-66. doi: 10.1126/science.abb8575.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias